Trial Outcomes & Findings for The Effect of Pseudoephedrine on Rhinitis and Sleep (NCT NCT00704496)
NCT ID: NCT00704496
Last Updated: 2017-10-18
Results Overview
sleep improvement by subjective questionnaires
Recruitment status
COMPLETED
Study phase
PHASE3
Target enrollment
34 participants
Primary outcome timeframe
3 years
Results posted on
2017-10-18
Participant Flow
data disposed of and no longer in existence
Participant milestones
| Measure |
Pseudoephedrine
Pseudoephedrine is a 240 mg PO per day
|
Placebo
Placebo arm
|
|---|---|---|
|
Overall Study
STARTED
|
0
|
0
|
|
Overall Study
COMPLETED
|
0
|
0
|
|
Overall Study
NOT COMPLETED
|
0
|
0
|
Reasons for withdrawal
Withdrawal data not reported
Baseline Characteristics
The Effect of Pseudoephedrine on Rhinitis and Sleep
Baseline characteristics by cohort
Baseline data not reported
PRIMARY outcome
Timeframe: 3 yearsPopulation: data disposed of and no longer in existence
sleep improvement by subjective questionnaires
Outcome measures
Outcome data not reported
SECONDARY outcome
Timeframe: 3 yearsPopulation: data disposed of and no longer in existence
daytime sleepiness by subjective questionnaires
Outcome measures
Outcome data not reported
Adverse Events
Placebo
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Pseudoephedrine
Serious events: 0 serious events
Other events: 0 other events
Deaths: 0 deaths
Serious adverse events
Adverse event data not reported
Other adverse events
Adverse event data not reported
Additional Information
Results disclosure agreements
- Principal investigator is a sponsor employee
- Publication restrictions are in place